The COVID-19 pandemic
is predicted to continue to wreak havoc on populations and economies around the
world, causing massive morbidity and mortality. Government must speed up the
development of safe and effective vaccines against COVID-19 as well as working
with manufacturers to ensure fair and equitable allocation of the vaccines for
all countries. This will necessitate adequate health-care system capability, as
well as strategies to improve vaccine confidence and acceptance among those who
administer it.
Many possible COVID-19 vaccines are being developed by scientists all over the world. At least seven separate
vaccines across three platforms have been carried out in countries as of
February 18, 2021. Vaccination is prioritized for vulnerable groups in all
countries. Simultaneously, more than 200 additional vaccine candidates are
being developed, with more than 60 of them in clinical trials.
COVID-19 vaccines that
have been given an Emergency Use Authorization (EUA) by the Food and Drug
Administration (FDA) are considered safe and effective based on the available
data, according to the Department of Health. The FDA has approved three
vaccines: Pfizer-BioNTech, Moderna, and Johnson & Johnson.
In people who have never
been infected with COVID-19, the PfizerBioNTech has a 95 percent efficacy rate.
The vaccine was equally successful across a wide range of people and factors,
including age, gender, race, ethnicity, and body mass index (BMI)—or the
existence of other medical conditions, according to the researchers. The
vaccine was shown to be 100 percent effective in preventing serious disease in
clinical trials.
In people with no
evidence of prior COVID-19 infection, the Moderna is 94.1 percent successful at
preventing symptomatic infection. In clinical trials, the vaccine appeared to
have high effectiveness among people of various ages, sexes, races, and
ethnicities, as well as those with underlying medical conditions (although as
mentioned above, the efficacy rate drops to 86.4 percent for people ages 65 and
older).
In the United States,
Johnson & Johnson has a 72 percent overall efficacy rate and an 86 percent
efficacy rate against serious disease. The efficacy of this vaccine has been
demonstrated to provide defense against the B.1.1.7 variant. According to FDA
analyses published in late February, in South Africa, where the B.1.351 version
was first discovered, there was 64 percent overall efficacy and 82 percent
efficacy against serious disease.
Although some COVID-19
vaccines have demonstrated high levels of effectiveness in clinical trials,
COVID-19 vaccines, like all vaccines, will not be 100 percent safe. WHO is
trying to make licensed vaccines as safe as possible so that they can have the
greatest impact on the pandemic.
Since COVID vaccines
have only recently been developed, it is too early to say how long COVID-19
vaccines will protect you. The question of how vaccines provide long-term
safety is still being researched. However, available evidence suggests that
most people who recover from COVID-19 develop an immune response that protects
them from reinfection for at least a period of time. Researchers are still
figuring out how effective this defense is and how long it lasts.
The vaccines are all intended to teach the body's immune system how to identify and block the virus that causes COVID-19 in a safe and effective manner. Immunity may be developed by vaccination, which reduces the risk of contracting the disease and its effects. Vaccination save lives for every stage of life. GET VACCINATED NOW!
References:
https://www.yalemedicine.org/news/covid-19-vaccine-comparison
https://images.app.goo.gl/EieXgcQFX1fDpB2F8
Comments
Post a Comment